跳至主要内容
临床试验/ACTRN12608000224325
ACTRN12608000224325进行中(未招募)不适用

A prospective, randomised, open-label, controlled study of safety and efficacy of the BioEnterics Intragastric Balloon (BIB) system in the treatment of obese participants with metabolic syndrome, with or without other obesity-related co-morbidities

Allergan Australia0 个研究点目标入组 66 人开始时间: 2008年4月30日最近更新:

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
66

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment

入排标准

年龄范围
18 Years 至 60 Years(—)
性别
All

入选标准

  • (i) Body Mass Index (BMI) between 30 & 40 kg/m2 with metabolic syndrome (ii) Failed attempts to lose weight with supervised weight loss programmes

排除标准

  • Specific Gastrointenstinal [GI] diseases/conditions (e.g. inflammatory; bleeding; dysmotility)
  • Prior gastric surgery; type 1 diabetes; untreated thyroid disease, hepatic or moderate to severe renal insufficiency; pregnancy; alcohol or drug dependence; psychiatric disorders; medication affecting weight or appetite

研究者

发起方
Allergan Australia

相似试验